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Abstract
Levodopa (L-dopa) effects on the cardinal and axial symptoms of Parkinson’s disease (PD) differ greatly, leading to
therapeutic challenges for managing the disabilities in this patient’s population. In this context, we studied the cerebral
networks associated with the production of a unilateral hand movement, speech production, and a task combining both
tasks in 12 individuals with PD, both off and on levodopa (L-dopa). Unilateral hand movements in the off medication state
elicited brain activations in motor regions (primary motor cortex, supplementary motor area, premotor cortex, cerebellum),
as well as additional areas (anterior cingulate, putamen, associative parietal areas); following L-dopa administration, the
brain activation profile was globally reduced, highlighting activations in the parietal and posterior cingulate cortices. For the
speech production task, brain activation patterns were similar with and without medication, including the orofacial primary
motor cortex (M1), the primary somatosensory cortex and the cerebellar hemispheres bilaterally, as well as the left-
premotor, anterior cingulate and supramarginal cortices. For the combined task off L-dopa, the cerebral activation profile
was restricted to the right cerebellum (hand movement), reflecting the difficulty in performing two movements
simultaneously in PD. Under L-dopa, the brain activation profile of the combined task involved a larger pattern, including
additional fronto-parietal activations, without reaching the sum of the areas activated during the simple hand and speech
tasks separately. Our results question both the role of the basal ganglia system in speech production and the modulation of
task-dependent cerebral networks by dopaminergic treatment.
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Introduction
Studies on individuals with Parkinson’s disease (PD) have
notably involved the investigation of the effects of dopaminergic
medication on cerebral blood flow at rest [1]. Some studies
reported no modifications of brain activation while others rather
found a global increase [2,3] or decrease [4,5] in cerebral activity
when comparing on medication vs. off medication state. Both
subthalamic nucleus (STN) stimulation and levodopa (L-dopa)
have proven to reduce hypermetabolism in the lenticular nucleus
and increase metabolism in the associative prefrontal cortex [6].
Interestingly, the response to L-dopa at rest depends on the
duration of exposure to the medication: individuals with PD
chronically treated by L-dopa have decreased regional cerebral
blood flow in the ventrolateral prefrontal and sensorimotor
cortices, but drug-naive patients display no levodopa-induced
modification of cerebral activation [7]. The significance of these
changes in response to L-dopa remains uncertain but could reflect
a modification of the thalamocortical projections by long-term L-
dopa treatment, at least at rest.
Using self-generated arm movements in untreated individuals
with PD, early functional neuroimaging studies reported reduced
regional cerebral blood flow (rCBF) within the main cortical
output areas of the basal ganglia, including the supplementary
motor area (SMA), dorsolateral prefrontal cortex (DLPFC) and
anterior cingulate cortex (ACG) [8–11]. These results were further
extended in more recent studies that also revealed that the
activation of some structures depends on the nature and
complexity of the task. Thus, although the anterior SMA (pre-
SMA) often appeared under-activated during hand movements,
over-activations within the caudal SMA, premotor (PM), M1,
inferior parietal and anterior cingulate cortices, as well as
cerebellar hemispheres have also been reported, suggesting that
these areas could be recruited to overcome the dysfunction of the
cortex-basal-ganglia-cortex motor circuit [12–15]. In addition, the
reduced activations reported within the SMA [9] and the lateral
PM cortex [16] appeared to be partly restored following
dopaminergic administration. Regarding M1 activation, the
evidence on the effect of medication is contradictory. While some
authors reported the restoration of activation after apomorphine
administration [9], others showed a reduction of the precentral
gyrus activation [17]. These contradictory findings could result
from the specific constraints of the task being performed, while
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inhibition of endogenous dopamine release by the exogenous
contribution of the medication may further complicate the matter
[18]. Finally, the putamen and thalamus have been shown to be
most responsive to levodopa, as compared with less responsive
motor cortical areas [19]. Thus, these findings stressed the need to
better understand the influence of dopaminergic treatments on the
cortical and subcortical circuits [17–19] underlying movement
production.
Motor network activations during PD speech production have
been studied using both positron emission tomography (PET) [20–
23] and functional magnetic resonance imaging (fMRI) [24–27].
These neuroimaging studies have documented that Parkinsonian
speech seemed to be related to an altered recruitment of the main
brain motor regions underlying speech production (orofacial
motor cortex, cerebellum) and an increased involvement of the
premotor and prefrontal cortices (DLPFC, SMA, superior
premotor cortex). Additional cerebral activation, such as the
recruitment of temporal regions, have also been observed off
medication [24,27], suggesting that a specific reorganization
underlies the altered activation pattern associated with PD speech.
In most PET experiments examining speech production in
individuals with PD off or on treatment, basal ganglia activation
barely reached statistical significance. A reduced SMA activation
[21,22,25] and a significantly greater activation in the right
primary orofacial sensorimotor cortex, as compared to controls
subjects, have also been reported following L-dopa intake. These
changes were interpreted as a compensatory phenomenon to
preserve speech in PD [25]. They also revealed increased
connectivity between the periaqueductal grey matter and basal
ganglia, posterior superior temporal gyrus, supramarginal and
fusiform gyri and inferior parietal lobule on the right side [26].
These modifications could reflect either a specific compensatory
phenomenon or a specific modification of the activation pattern
underlying brain dysfunctions of PD speech. In either case, this
pattern of modifications does not parallel the one associated with
hand motor tasks. Dysarthria usually worsens with disease
progression, which suggests that it is also linked to the progression
of the pathological processes to non-dopaminergic brain circuits
[28–31]. Specifically, one would expect neuronal losses of
additional areas of motor control to be involved, such as the
pre-supplementary cortex [32], the thalamus [33] or the
mesocortical system [34].
To date, no study has investigated the influence of dopaminer-
gic treatment on the patterns of neural activation during hand and
speech movements in the same group of individuals with PD.
Furthermore, although in daily life speech is often accompanied by
hand or other movements, very few studies have examined such
dual tasking in PD [35–38]. A few neuroimaging studies have
examined the performance of simultaneous movements in PD, as
it is well-known that individuals with PD have difficulties
performing complex, simultaneous or sequential movements
[39–43]. Most of these studies have used bimanual movements
[44,45], or dual motor and cognitive tasks [46], rather than
simultaneous limb and speech movements. While some of
important issues regarding the neural bases of hand and speech
movements in PD have been addressed, the functional brain
activations underlying the difficulty these patients have in
simultaneously performing both together remain unclear. There-
fore, using fMRI, we investigated the influence of dopamine
treatment on the patterns of neural activation underlying hand
movement (HM) and speech production (SP) performed both
alone and simultaneously in individuals with PD. Even if the
(HM+SP) movement combination movement is unnatural and
experimental, it allows for the combination of the two HM and SP
movements: it should be considered as a combined task, and not
a proper dual-task comprising strictly independent tasks, as it did
not involve any cognitive conflict in response selection between the
HM and SP tasks. The motor programming was identical for the
two modalities, (i.e., selection of the same response among four
possibilities) and only the motor execution differed [24]. More-
over, it cannot be considered as a co-speech gesture also as it is not
unconsciously self-generated by the participants themselves. We
hypothesized that the brain activation profiles for HM and SP
tasks performed alone would both be modulated following L-dopa
intake. In a previous study, we observed that the brain activations
recorded during the HM+SP combined task were the sum of the
activations obtained when each of the tasks was performed
separately in healthy subjects, while this was not the case in
untreated individuals with PD [24]. Our second hypothesis was
that L-dopa would restore such summation, as is the case for
a bimanual simultaneous task [44].
Materials and Methods
1. Patients
Twelve right-handed (Edinburgh handedness questionnaire
.80%) patients with PD were recruited in the Neurological
wards of the Grenoble (n = 6) and Lyon (n= 6) University
Hospitals. Demographic and clinical characteristics of the patients
are summarized in Table 1. All patients fulfilled the UK
Parkinson’s disease Brain Bank Criteria [47] for the diagnosis of
idiopathic PD and presented with predominant akinetic-rigid
symptoms.
All patients were studied first without (off), and then with (on)
anti-Parkinsonian medication, during two consecutive fMRI
sessions of one hour each. Off medication, patients were scanned
after an overnight fast, i.e. at least 12 hours of PD treatment
withdrawal. The on medication session was undertaken with
patients in their best on motor state, 45 to 60 minutes after
administration of a suprathreshold dose of L-dopa (120% of the
usual morning dose; see Table 2). Unblinded evaluation of the
patients’ global motor disability was performed before each fMRI
session using the motor section of the Unified Parkinson’s Disease
Rating Scale (UPDRS, part III) [48]. Only patients with mild to
moderate mostly akineto-rigid symptoms (with no or little tremor
off, and no or little dyskinesia on) were included to ensure that they
could perform the tasks. The patients had moderate speech
impairment and were able to produce intelligible speech allowing
for the performance of the speech production task. The off and on
medication UPDRS scores were statistically compared (paired
Student t test, p,0.05; STATISTICA 7.1, Statsoft, Tulsa, USA)
to appreciate the impact of the treatment.
2. Ethics Statement
The study (project nu 06-CHUG-6) was conducted in accor-
dance with the Declaration of Helsinki [49], approved by the local
Ethics Committee Review Board (Comite´ de Protection des
Personnes [CPP] pour la recherche biome´dicale, Centre Hospi-
talier Universitaire de Grenoble [CHUG], France). The patients
were included after providing written informed consent.
3. Experimental Paradigms
The experimental protocol included 3 motor tasks [24]:
– Hand movement (HM) - a freely chosen sequence of movements
performed with the right hand, moving a non-magnetic fMRI-
compatible joystick (Current Designs, Philadelphia, USA) in 4
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possible directions (forward, backward, right and left), starting
from and returning to the neutral position;
– Speech production (SP) - a freely chosen speech sequence, using 4
possible words (‘‘Up’’, ‘‘Down’’, ‘‘Right’’ and ‘‘Left’’);
– Combined task ([HM+SP]) - a freely chosen sequence of joystick
movements performed with the right hand together with the
speech description of the associated directions (‘‘Up’’, for the
forward direction; ‘‘Down’’, for the backward direction;
‘‘Right’’; and ‘‘Left’’).
They represented a particular version of externally-paced tasks,
since an additional dimension was introduced by the choice
among the 4 possibilities. Prior to the fMRI trials, patients had
ample opportunity to practice the tasks, during which they were
instructed to respond to each visual stimulus, i.e. the word ‘‘action’’
presented every two seconds for 500 milliseconds (ms). Patients
were asked to avoid pre-established sequences of movement
directions. They were allowed to use the same direction and/or
produce the same word several times in a row. The joystick used
for the HM and (HM+SP) tasks was connected to a control case
enabling the synchronization of the visual stimulus with image
acquisition. The setting also enabled a posteriori monitoring of
performance, as well as analysis of the direction of the movements.
During a rest condition (the word ‘‘rest’’ appeared repeatedly on
the screen), patients were required to remain still, without making
any movement or speaking. For technical reasons, including the
noisy fMRI environment, we were not able to monitor the SP task
performance. Nevertheless, a posteriori questioning of the patients
ensured that the tasks had been performed according to the
instructions.
4. Functional MRI Procedure
To ensure patients’ comfort, a block-design was chosen, each
motor task corresponding to an fMRI run of about 7 minutes’
duration. Each run alternated 10 blocks of rest and 10 blocks of
action (HM, SP or tasks HM+SP), each block including 10 trials,
for a total of 100 trials. The order of the fMRI runs was
counterbalanced between conditions and patients. fMRI data were
obtained on a 3 Tesla (T) MRI scanner (Bruker Medspec S300 -
IFR 1, Biomedical NMR and Neurosciences, Grenoble, France),
equipped with an emitting/receiving head coil. For each fMRI
run, 160 volumes covering the whole brain with 40 adjacent axial
3.2 mm thick slices were acquired using a BOLD-contrast multi-
slice T2*-weighted single-shot echo-planar imaging (EPI) sequence
(echo time (TE) = 30 ms, repetition time (TR)= 2500 ms, flip
angle = 77u, field of view (FOV) = 2166216 mm2, matrix size
72672, voxel size = 36363.2 mm3). T1-weighted 3D magnetiza-
tion prepared rapid acquisition gradient echo (MP-RAGE)
anatomical images of the whole brain were also acquired
(TR=2500 ms, TE= 3.89 ms, TI = 900 ms, flip angle = 8u,
FOV=25662246176 mm3, voxel si-
ze = 1.3361.7561.375 mm3).
5. Behavioral Data Analysis
Direction and response times (RT) for the HM and (HM+SP)
tasks were recorded during image acquisition and processed off
line. RTs shorter than 150 ms or longer than 1500 ms were
discarded. Mean RT and performance rate were computed for
each patient. The influence of task (single vs. double) and
medication (off vs. on) was analyzed using non-parametric Wilcoxon
tests with a corrected p-value,0.025 for multiple comparisons.
6. fMRI Data Analysis
fMRI data analysis was performed using SPM5 software
(Wellcome Department for Cognitive Neuroscience, London,
UK) [49]. First-level analyses were carried out for each patient,
yielding parametric statistical maps generated for each motor task
both off and on medication. Patient 4 was not able to perform the
SP task off medication and patient 7 the HM task on medication.
The first-level contrasts were introduced within second-level
analyses, using a two-factor ANOVA model with the motor tasks
(HM, SP and HM+SP) and treatment conditions (off or on
medication) as repeated measures. Only cerebral areas whose
statistical thresholds corresponded to probabilities pFWE-cor-
rected,0,05 at the voxel level and activation foci for which the
number of voxels was equal or superior to k = 10 were retained (Z-
scores.5.20). When this statistical processing did not make it
possible to detect any activation, a non-corrected statistical
threshold of puncorrected,0,001 was applied at the voxel level (Z-
scores.3.10). The activation coordinates were transformed into
Table 1. Demographic data of the patients.
Patients Sex Symptom laterality predominance Age (years) Disease duration (years)
1 M R 64 8
2 M L 53 12
3 M R 61 6
4 M R 67 5
5 M R 52 12
6 M L 55 8
7 M L 58 8
8 M L 51 8
9 M L 69 14
10 F L 65 15
11 M L 58 9
12 M L 64 12
Mean 6 SD 59.866.1 9.863.2
F = female; L = left; M =male; R = right; SD = Standard deviation.
doi:10.1371/journal.pone.0046541.t001
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a standard stereotactic space [50]. Between-medication state and
between-task comparisons allowed for further detailed analysis.
Uncorrected p-values,0.001 (Z-scores.3.10) were considered
significant for these contrasts.
Results
1. Clinical and Behavioral Data
Group analysis confirmed that the total motor scores of the
UPDRS and the Hoen and Yahr scale (Table 2) decreased
significantly following the administration of L-dopa (75.2% of
improvement for the UPDRS, p,0.001; 41.9% of improvement
for the Hoen and Yahr, p,0.001). The improvement for rigidity,
axial signs and akinesia sub-scores was 66.7%, 71.1% and 75.9%
respectively (p,0.001). The improvement in speech production as
assessed using item 18 of the UPDRS III was also significant,
although more limited (38.5%, p,0.001).
The patients correctly performed the tasks under the two
experimental conditions, although the number of movements was
greater on medication than off (HM off: 62618; on: 78615;
HM+SP off: 64618; on: 78612). The effect of medication on the
number of trials was significant both for the HM task (z = 2.85;
p,0.005) and for the combined task (z = 2.90; p,0.005). There
was no effect of task on the number of movements. Regarding
response time, there was no effect of either task or medication,
although response times were slightly shorter under medication
than off (HM off: 6596173 ms; on: 5566101 ms; HM+SP off:
6266145 ms; on: 5616116 ms). Neither task nor medication
affected the distribution of the movements’ direction.
2. fMRI within-group Comparisons and between
Medication State Comparisons
2.1. Hand movement. At a comparable statistical level
(Table 3), the brain activation profile off L-dopa strongly involved
the right cerebellum and left motor/premotor regions; recruitment
of the anterior cingulate cortex and the superior and inferior
parietal lobules were also noted, as well as that of the putamen
(Fig. 1a). Administration of L-dopa led to a focalization of
activations, revealing weak activations in the right posterior
cingulate gyrus and the left inferior parietal lobule (Fig. 1b).
Cerebral activations in the off vs. on L-dopa comparison involved
significant right-lateralized regions in the anterior insula and the
putamen; for the on vs. off L-dopa comparison, no suprathreshold
clusters were found for the HM task (Table 4).
2.2. Speech production. No significant brain activations
survived the pFWE-corrected,0.05 statistical level. Values at
puncorrected,0.001 (Table 5) revealed similar activations for the
off and on L-dopa conditions, including the bilateral orofacial M1
and cerebellar hemispheres, as well as the left premotor, primary
somatosensory, supramarginal and anterior cingulate cortices,. In
terms of cluster sizes, the off L-dopa (Figure 2a) brain activation
profile was larger than on L-dopa (Figure 2b) at the levels of
premotor and anterior cingulate cortices, and cerebellum. For the
SP task, no suprathreshold clusters were detected either for off vs.
on L-dopa or on versus off L-dopa.
2.3. Combined task. Activations within the right cerebellum
were seen off L-dopa (Fig. 3a). On L-dopa, comparable cerebellar
activations were seen (Table 6), although there was a focalization
of the areas recruited (Fig. 3b). Additional left-sided activations
were seen in the medial premotor cortex, the post-central gyrus
and the inferior parietal lobule. Off versus on L-dopa comparison for
the (HM+SP) task revealed an activation within the right median
temporal gyrus. No suprathreshold clusters were detected on versus
off L-dopa (Table 7).
3. fMRI between-task Comparisons
Off L-dopa, no (HM+SP) vs. HM task activations were detected;
on L-dopa, there was a right-sided M1 activation (Table 8). Off L-
dopa, the (HM+SP) vs. SP contrast was associated with left
activations within the cerebellum, premotor cortex, superior
temporal gyrus, as well as superior and inferior parietal lobules.
On L-dopa, analyses revealed no suprathreshold clusters (Table 9).
Discussion
Off medication, unilateral hand movements yielded brain
activations in the right cerebellum, left motor/premotor regions,
anterior cingulate cortex, superior and inferior parietal lobules, as
well as in the putamen. Under L-dopa, the brain activation profile
was globally reduced, restricted to activations in the right posterior
cingulate gyrus and the left inferior parietal lobule. For the speech
production task, brain activation patterns were similar with and
without medication, including the bilateral orofacial M1 and
cerebellar hemispheres, as well as the premotor, primary
somatosensory, supramarginal and anterior cingulate cortices, all
left-sided. The combined task yielded a right cerebellar activation,
both without and under L-dopa. On L-dopa, there were additional
left-sided activations in the medial premotor cortex, post-central
gyrus and inferior parietal lobule.
1. Hand Movements in PD
Behavioral measurements showed an improvement in the ability
to respond to commands and initiate the hand movement
following L-dopa intake, as evidenced by the increased number
of movements. The shortening in response time did not reach
significance, which is not surprising as, unlike other studies that
reported an effect of medication on reaction time [51,52], we did
not use a reaction time protocol. The reduced performance of
hand movements when off L-dopa could be related to the
overactivation of the cortico-cerebello-cortical circuit and the loss
of brain activation selectivity resulting from the effort to overcome
the dopaminergic-denervation-dependent akinesia [12,14]. Sever-
al neuroimaging studies supported the hypothesis that an increased
activation of the cortico-cerebello-cortical circuitry may compen-
sate for the cortico-striato-cortical motor loop dysfunction [12–
15,53,54]. Despite the stronger recruitment of the cerebellum in
the off medication brain profile and the reductions in brain
activation following L-dopa intake, the between-medication state
comparison did not reveal any cerebellar over-activation in the
present study. Other authors also failed to observe this cerebellar
over-activation in individuals with PD, off medication [55–57],
including one using the same experimental paradigms [24]. Such
discrepancies may depend on whether the brain activation profile
of PD patients’ off medication is compared with the on medication
state or with controls subjects, highlighting the fact that
medication does not restore a normalized pattern.
The strong fronto-parietal involvement off L-dopa included the
inferior and superior parietal gyri (BA 40 and 7), with pre-
dominance in the left hemisphere. In contrast to earlier findings
[24], there was no associated visual activation, although the pacing
stimuli were presented visually. Under medication, the brain
activation profile, including the parietal network, was globally
reduced, although a left-sided activation persisted within the
inferior parietal lobule. It has been shown that improved
movement performance is associated with a reduction of brain
compensatory activations following L-dopa or subthalamic nucleus
stimulation, that is, after restoration of the more efficient cortico-
striato-thalamo-cortical pathway [16,18,58,59]. Our results sug-
gest that although dopaminergic administration can improve
fMRI, L-dopa, Hand and Speech Movements
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Figure 1. Patterns of brain activation during the hand movement task in PD patients (a – off L-dopa; b – on L-dopa). Activation
thresholds correspond to corrected (FWE) p-values,0.05. Without medication, brain activations were found in the right cerebellum, left motor/
premotor regions, anterior cingulate cortex, superior and inferior parietal lobules, and putamen; following L-dopa intake, the brain activation profile
was globally reduced, restricted to weak activations in the right posterior cingulate gyrus and the left inferior parietal lobule.
doi:10.1371/journal.pone.0046541.g001
Table 3. Cerebral sites of maximal hemodynamic responses during the hand movement (HM): Main effects (pFWE-corrected,0.05,
k$10) of L-dopa medication states.
off L-dopa on L-dopa
Cerebral area BA L/R x y z Z-score k x y z Z-score k
Precentral gyrus 4 L 219 227 56 6.12 521u
Medial frontal gyrus 6 L 23 218 52 5.95 151#
Frontal sub-gyral 6 R 23 26 52 5.51 29
Anterior cingulate gyrus 24 L 21 0 45 5.62 151#
Posterior cingulate gyrus 31 R 18 248 224 5.26 20
Superior parietal lobule 7 R 34 253 52 5.20 64‘
Inferior parietal lobule 40 L 240 253 47 6.77 521u 230 238 51 5.63 12
Inferior parietal lobule 40 R 31 244 37 5.88 64‘
Inferior parietal lobule 40 R 47 230 38 5.56 28
Putamen L 227 212 4 5.29 14
Cerebellum (dentate) L 214 250 224 5.42 18
Cerebellum (dentate) R 15 250 221 7.61 251*
Cerebellum (vermis) R 2 262 214 6.19 251*
Cerebellum (hemisphere) R 26 264 225 6.09 251*
Cerebral activation locations refer to maximal hemodynamic response sites. L/R: left/right; BA: Brodmann’s area; x, y, z: mediolateral, rostrocaudal and dorsoventral
Talairach coordinates; k: cluster size (number of voxels); u/#/‘/*: parts of the same cluster.
doi:10.1371/journal.pone.0046541.t003
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motor performances in PD patients, it does so through
a reorganized dopaminergic system: the cerebellar and parietal
implications off medication were reduced following L-dopa
administration. Nevertheless, the only regions surviving the
between medication condition comparisons were found in the
right anterior insula and putamen.
2. Preservation of Speech in PD
In both off and on medication conditions, we found premotor/
motor brain activations in the frontal cortex and cerebellum
similar those previously reported [20–27]; activations within the
left anterior cingulate cortex and supramarginal gyrus were also
observed. These regions could be part of a fronto-parietal
compensatory mechanism enabling the preservation of speech in
PD [24,27]. Indeed, the speech production task was likely driven
Table 4. Cerebral sites of maximal hemodynamic responses during the hand movement (HM): Between medication state
comparisons (puncorrected,0.001, k$10).
off vs. on L-dopa on vs. off L-dopa
Cerebral area L/R x y z Z-score k x y z Z-score k
Insula (anterior) R 34 8 25 3.66 19 No suprathreshold clusters
Putamen R 26 8 0 3.28 19
Cerebral activation locations refer to maximal hemodynamic response sites. L/R: left/right; BA: Brodmann’s area; x, y, z: mediolateral, rostrocaudal and dorsoventral
Talairach coordinates; k: cluster size (number of voxels).
doi:10.1371/journal.pone.0046541.t004
Figure 2. Patterns of brain activation during the speech production task in PD patients (a – off L-dopa; b – on L-dopa). Activation
thresholds correspond to uncorrected p-values,0.001. Brain activation patterns were similar with or without medication, including the bilateral
orofacial M1 and cerebellar hemispheres, as well as the left-sided premotor, primary somatosensory, supramarginal and anterior cingulate cortices.
doi:10.1371/journal.pone.0046541.g002
fMRI, L-dopa, Hand and Speech Movements
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by the cognitive decision of the direction rather than internal
vocalization, as no associative auditory activation was found. As
observed for the HM single task, an overall reduction in brain
activations was observed, being much more important in the
cerebellum and the premotor, anterior cingulate and supramar-
ginal cortices, than in the motor regions. Orofacial activity seemed
to respond somewhat like hand activity, albeit to a lesser extent.
Others have reported a right orofacial sensorimotor cortex
compensatory activation in PD patients on medication when
compared to control subjects [25]. Lateralisation of basal ganglia
dysfunction in PD has also to be taken into account, since evidence
of ‘‘a crucial role of the right basal ganglia in the maintenance of
Table 5. Cerebral sites of maximal hemodynamic responses during speech production (SP): Main effects (puncorrected,0.001, k$10)
of L-dopa medication states.
off L-dopa on L-dopa
Cerebral area BA L/R x y z Z-score k x y z Z-score k
Precentral gyrus 4 L 246 215 39 4.06 95u 246 215 39 4.29 94‘
Precentral gyrus 4 R 41 212 33 4.67 58 41 212 28 4.09 36*
Medial frontal gyrus 6 L 26 26 55 4.97 123# 23 215 57 3.97 27
Postcentral gyrus 2 L 235 221 33 4.40 95u 238 221 28 4.32 94‘
Postcentral gyrus 2 R 36 218 30 4.07 36*
Anterior cingulate gyrus 24 L 26 0 47 4.63 123# 26 5 42 3.94 33
Supramarginal gyrus 40 L 240 247 32 3.71 33 211 264 219 3.73 10
Cerebellum (dentate) L 211 264 219 3.73 10
Cerebellum (hemisphere) L 225 262 227 5.79 149 227 262 227 4.01 10
Cerebellum (hemisphere) R 26 264 225 5.25 118 26 264 225 4.07 17
Cerebral activation locations refer to maximal hemodynamic response sites. L/R: left/right; BA: Brodmann’s area; x, y, z: mediolateral, rostrocaudal and dorsoventral
Talairach coordinates; k: cluster size (number of voxels); u/#/‘/* : parts of the same cluster.
doi:10.1371/journal.pone.0046541.t005
Figure 3. Patterns of brain activation during the [hand movement + speech production] task in PD patients (a – off L-dopa; b – on L-
dopa). Activation thresholds correspond to corrected (FWE) p-values,0.05. Without L-dopa, the combined task yielded a right cerebellar activation.
Under L-dopa, comparable cerebellar activations were seen, along with additional left-sided activations in the medial premotor cortex, post-central
gyrus and inferior parietal lobule.
doi:10.1371/journal.pone.0046541.g003
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isochronous speech rhythms’’ has been recently reported when
comparing performances of two homogenous groups of PD
patients, presenting with right and left-sided predominant
symptoms [60].
A key connection between the basal ganglia and the cerebellar
motor circuits seems to be altered in PD and a reduction of brain
activation within both circuitries may participate in the de-
velopment of dysarthria. Our data suggest that compensatory
strategies could involve, amongst others, temporal regions which
are known to play a role in SP mechanisms, the insula, and frontal
areas including the lateral premotor cortex and the anterior
cingulate gyrus (ACG). All these regions could be part of
a surrogate network able to provide the functionality needed to
support SP, even if SP is dysarthric. Among these regions, the
ACG is one of the main basal ganglia circuit outputs (the limbic
one). On the other hand, the cerebellum is tightly connected with
frontal regions, including Broca’s area and the lateral premotor
cortex. The additional network activated in our patients could
therefore be recruited as compensatory circuitry of dysarthric
speech, enabling inter-circuit compensations, either in the fronto-
striatal or the cerebro-cerebellar circuitries. It is possible that in
early PD, basal ganglia dysfunction primarily affects speech and
leads to mild dysarthria, while with the disease progression severe
dysarthria results from additional dysfunction of the cortex-
cerebellum circuitry. It is known that worsening of dysarthria with
disease progression parallels an increasing severity of non-
dopaminergic cerebral lesions [28,29,31]. One key structure could
be the thalamus [33], since it relays to the cortex information
arising in both the cerebellum and the basal ganglia loops.
The key-role of the cerebellum [61–63] and non-dopaminergic
neural circuits in the anatomo-functional substrate of vocal
communication could partly explain the resistance of Parkinsonian
speech to L-dopa. Even if some studies pointed out beneficial
effects of L-dopa on PD speech [64,65], several studies that have
explored speech parameters in PD have demonstrated the lack of
significant change between the two medication condition [66].
According to the classical cortico-subcortical circuit models first
defined in the early nineties [67–69], and further developed since
[70,71], the circuits operate in a segregated and parallel fashion.
The concept of closed and open circuits allows for cross-
communication between circuits [72]. Apart from the motor
circuit, which connects the primary motor/lateral premotor
cortices and the SMA via the putamen, parallel non-motor loops
originate from various regions of the basal ganglia and terminate
in the DLPFC (prefrontal loop), orbito-frontal cortex (lateral
orbito-frontal loop) or even anterior cingulate cortex (limbic loop).
It is therefore possible that the alteration of the motor loop be
compensated for, albeit imperfectly, by the recruitment of a non-
motor circuit. The motor deficit of PD speech could depend on
such a compensatory pathway: perceptual evaluation through the
UPDRS speech item demonstrated that the patients presented
with mild dysarthria, whether on or off medication. Indeed, clinical
data revealed a significant improvement of the UPDRS motor
scores under medication, but as already reported, improvement
was lesser for speech production [73,74]. Our results regarding the
speech production task in PD are thus consistent with the idea that
the recruitment of non-dopamine dependent cerebral compensa-
tory mechanisms allows for acceptable speech performance.
3. Combining Movements in PD
Studies using dual-task paradigms combining simultaneous but
independent verbal and manual tasks are scarce [75–77], in-
cluding in PD patients [35–38]. Yet, such concurrent tasks are
common in daily activities and their performance is often impaired
Table 6. Cerebral sites of maximal hemodynamic responses during the combined [HM+SP] task: Main effects (pFWE-corrected,0.05,
k$10) of L-dopa medication states.
off L-dopa on L-dopa
Cerebral area BA L/R x y z Z-score k x y z Z-score k
Medial frontal gyrus 6 L 23 18 60 5.30 10
Postcentral gyrus 3 L 230 232 43 5.27 43#
Postcentral gyrus 40 L 240 230 51 5.07 43#
Inferior parietal lobule 40 L 230 238 51 5.04 43#
Cerebellum (dentate) R 12 256 219 5.87 94* 15 250 221 5.60 71
Cerebellum (hemisphere) L 227 262 227 5.68 11
Cerebellum (hemisphere) R 26 264 225 5.84 94*
Cerebral activation locations refer to maximal hemodynamic response sites. L/R: left/right; BA: Brodmann’s area; x, y, z: mediolateral, rostrocaudal and dorsoventral
Talairach coordinates; k: cluster size (number of voxels); *, #: parts of the same cluster.
doi:10.1371/journal.pone.0046541.t006
Table 7. Cerebral sites of maximal hemodynamic responses during the combined [HM+SP] task: Between medication condition
comparisons (puncorrected,0.001, k$10).
off vs. on L-dopa on vs. off L-dopa
Cerebral area BA L/R x y z Z-score k x y z Z-score k
Temporal sub-gyral 21 R 47 29 29 3.94 28 No suprathreshold clusters
Cerebral activation locations refer to maximal hemodynamic response sites. L/R: left/right; BA: Brodmann’s area; x, y, z: mediolateral, rostrocaudal and dorsoventral
Talairach coordinates; k: cluster size (number of voxels).
doi:10.1371/journal.pone.0046541.t007
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in PD [78]. The combined task was specifically formulated to
avoid any cognitive conict; this was an advantage for assessing the
neural correlates of simultaneous task performance, without
cognitive overload, which is usually a confounding factor in
dual-task paradigms. The combined task paradigm was not
a classical dual task one, as it did not involve strictly independent
tasks, that is, it did not induce cognitive conict in response
selection between the HM and SP tasks. For both HM and SP, the
motor processes yielded the selection and planning of the same
response (left, right, up, down) among four possibilities (i.e. the four
movement directions). Only the motor execution (hand and
orofacial movements) differed in terms of the muscles involved in
production. Thus, PD patients did not face any conflict, but rather
facilitation, in response selection during the task. PD individuals
have been shown to demonstrate trouble when performing
complex dual tasks and exhibit greater activations in the
cerebellum, premotor area, precuneus, parietal and prefrontal
cortices [46] than control subjects. In a previous study, in control
subjects, but not in PD patients off medication, our combined task
yielded the sum of the brain activations obtained during hand
movement and speech production performed separately [24]. This
was interpreted as the patients’ functional prioritization of the
HM, SP being therefore associated with sub-threshold cerebral
activations. It could also have reflected the inability of PD patients
to intrinsically engage in the motor coordination necessary to
perform a combined task. Indeed, due to the additive nature of the
two tasks, the combined task represented an easier task to
generate.
In the present study, our data are in agreement with those
observed previously in patients off medication. Moreover, the
summation of the two networks was also absent when the patients
were on medication. This is congruent with the fact that SP
activations never reached the corrected statistical threshold, even
during the performance of the single task. These results suggest
that the loss of capacity-sharing in combined movements did not
improve with L-dopa, contrary to our a priori hypothesis. In fact,
weak activations, restricted to the single right cerebellum, were
revealed off L-dopa; this lateralization suggested that it was related
to the hand movement part of the combined task. Following L-
dopa administration, left-sided regions were activated in a pre-
motor fronto-parietal network. Activations of these regions were
also seen during the single hand movements, and interpreted as
possible compensatory recruitments. These regions, possibly
involved in compensatory pathways, were highlighted by the
between-task comparisons (Tables 8 and 9). Thus, unlike what was
seen for the single tasks performed separately, this activation
pattern suggests that PD patients may rely on this network for
simultaneous motor performance [14,79,80]. Palmer et al. [44]
showed that during bimanual movements in PD, L-dopa partially
normalized the effective connectivity and temporal patterns of
activity. As already stressed by Brown [81], the authors related the
patients’ inability to perform two movements simultaneously to the
impaired capacity of binding the widespread cortical and sub-
cortical areas underlying dual-task performance. They suggested
that L-dopa restored effective communication between these areas,
and/or reduced ‘‘the excessive beta-band synchronization that
permeates widespread areas in the cortex and basal ganglia’’
(pages 701–702). Our results do not support the idea that L-dopa
can restore coordinated cortical/sub-cortical recruitments in dual-
tasks, although limb motor function appeared to be more
dopamine-driven (HM) than speech.
Table 8. Cerebral sites of maximal hemodynamic responses highlighted by between-task comparisons under off and on L-dopa
conditions: Combined (HM+SP) task vs. Hand movement (HM) task (puncorrected,0.001).
off L-dopa on L-dopa
Cerebral area BA L/R x y z Z-score k x y z Z-score k
Precentral gyrus 4 R No suprathreshold clusters 41 215 46 4.06 18
Cerebral activation locations refer to maximal hemodynamic response sites. L/R: left/right; BA: Brodmann’s area; x, y, z: mediolateral, rostrocaudal and dorsoventral
Talairach coordinates; k: cluster size (number of voxels).
doi:10.1371/journal.pone.0046541.t008
Table 9. Cerebral sites of maximal hemodynamic responses highlighted by between-task comparisons under off and on L-dopa
conditions: Combined (HM+SP) task vs. Speech production (SP) task (puncorrected,0.001).
off L-dopa on L-dopa
Cerebral area BA L/R x y z Z-score k x y z Z-score k
Paracentral lobule 31 L 23 218 44 3.85 11 No suprathreshold clusters
Superior temporal gyrus 41 L 240 232 17 4.14 16
Superior parietal lobule 7 L 227 256 58 4.06 177*
Inferior parietal lobule 40 L 243 235 48 4.41 177*
Postcentral gyrus 40 R 52 224 17 3.64 11
Cerebellum (dentate) R 18 250 224 4.54 67
Cerebral activation locations refer to maximal hemodynamic response sites. L/R: left/right; BA: Brodmann’s area; x, y, z: mediolateral, rostrocaudal and dorsoventral
Talairach coordinates; k: cluster size (number of voxels);
*parts of the same cluster.
doi:10.1371/journal.pone.0046541.t009
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4. Methodological Issues
Individuals with PD patients underwent the fMRI experiment
without anti-Parkinsonian medication. Since the off medication
state was evaluated in the morning of the experiment, and in order
to minimize any differential effects across conditions, we counter-
balanced the order of the experimental conditions across subjects.
The patients who participated in this study represented a homog-
enous group of PD patients and may not reflect the range or
variability of the disease. They were all relatively young patients,
most of them in accordance with the required inclusion criteria for
deep brain stimulation. Under the off medication condition, the
patients did not have any tremor. They were predominantly
akinetic-rigid, and one could wonder what would have been our
findings with tremor predominant patients with PD. It is hard to
anticipate whether the same findings would be obtained in such
a sub-group of patients; to our knowledge, no distinction has been
suggested so far regarding speech pathophysiology of akinetic-rigid
vs. tremor PD patients. All patients were producing intelligible
speech (cf. Table 2; mean UPDRS item 18 speech
score = 1.360.5; the worst score being 4) and unfortunately, we
were not able to record speech production either inside or outside
the fMRI scanner: we acknowledge that another clinical measure
for speech production should have provided a differentiated
picture of the patients’ potential deficit in this domain. Altogether,
these methodological aspects have to be taken into account when
interpreting the results, possibly restricting generalization.
Conclusions
Our results question both the role of the basal ganglia system in
speech production and the modulation of task-dependent cerebral
networks by dopaminergic treatment. Whereas the hand move-
ment brain network is sensitive to dopaminergic medication, the
brain activation patterns of speech production appear to undergo
little changes following medication. Even if different compensatory
circuits are activated in PD to try and overcome difficulties in
performing hand and speech movements, notably temporal
regions for speech production, recruitment of the associative
parietal cortex seems to be an alternative in tasks sharing
programming modalities. While conflicting dual task might result
in preferential execution of one of the two tasks performed
simultaneously, the combined task we used in this study did not
lead to positive synergistic effect under the on medication state.
Further experiments enabling the concomitant recording of speech
and hand movement, both conflicting and synergistic, are required
to confirm such finding.
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